Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Average Target Price of $7.50

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $7.67.

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Friday, September 4th. BTIG Research restated a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, October 5th.

Institutional Trading of Gain Therapeutics

Several large investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in Gain Therapeutics during the 2nd quarter worth approximately $1,283,000. Potomac Capital Management Inc. bought a new position in Gain Therapeutics in the fourth quarter worth approximately $3,252,000. Apollon Wealth Management LLC grew its stake in Gain Therapeutics by 33.7% in the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock valued at $51,000 after acquiring an additional 6,675 shares during the period. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics in the second quarter valued at approximately $277,000. Finally, HighTower Advisors LLC acquired a new stake in Gain Therapeutics in the second quarter valued at approximately $35,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Gain Therapeutics Trading Up 1.5%

NASDAQ GANX opened at $1.64 on Friday. The business has a 50 day simple moving average of $1.82 and a 200 day simple moving average of $1.83. Gain Therapeutics has a one year low of $1.53 and a one year high of $4.34. The stock has a market capitalization of $71.57 million, a P/E ratio of -3.28 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Research analysts expect that Gain Therapeutics will post -0.50 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.